Bio News
Cytokinetics’ heart disease treatment Myqorzo met both efficacy goals in a phase 3 trial for nonobstructive hypertrophic cardiomyopathy (HCM). In the trial, named ACACIA, Myqorzo demonstrated statistically significant improvements in heart failure symptoms and cardiovascular health. The success is expected to expand the indications for Myqorzo, which is already approved as a treatment for obstructive HCM, and generate annual sales of up to $5 billion (approximately 7.25 trillion won).
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
